Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
-
Source:
A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
تفاصيل العنوان
-
Source:
A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers
تفاصيل العنوان
-
Source:
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.
تفاصيل العنوان
-
Source:
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 Plus Carboplatin and Paclitaxel in Subjects With Selected Solid Tumors.
تفاصيل العنوان
-
Source:
A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers.
تفاصيل العنوان
-
Source:
A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
تفاصيل العنوان
-
Source:
A Phase 1, Open-label Study of SNX-5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase
تفاصيل العنوان
